Download PDF
Suchttherapie 2022; 23(04): 198-209
DOI: 10.1055/a-1912-0382
Fort- und Weiterbildung

Drogeninduzierte Psychosen

Drug-induced Psychosis
Oliver Pogarell
,
Gabi Koller
,
Kristina Adorjan
› Further Information
Also available at
    Permissions and Reprints

Substanzkonsumstörungen und Psychosen stehen häufig in einem kausalen Zusammenhang. Dieser kann uni- oder bidirektional sein – oder beide Störungen beruhen auf gemeinsamen ätiopathogenetischen Faktoren. Substanzen wie Cannabinoide, Stimulanzien oder Halluzinogene scheinen wichtige Ko-Faktoren für die Entwicklung einer (sekundären) Psychose darzustellen. Der Beitrag gibt einen Überblick über die Substanzgruppen, Diagnostik und Therapie.

Abstract

Substance use disorders and psychoses are often causally related. This causal relationship can be uni- or bidirectional – or both disorders are based on common etiopathogenetic factors. Substances such as cannabinoids, stimulants or hallucinogens seem to be important cofactors for development of a (secondary) psychosis. This article gives an overview of substance groups, diagnostics and therapy.

Key words

substance use disorders - substance-induced psychoses - cannabinoids - stimulants - hallucinogens

Schlüsselwörter

Substanzkonsumstörungen - substanzinduzierte Psychosen - Cannabinoide - Stimulanzien - Halluzinogene


Publication History

Article published online:
08 November 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Regier DA, Farmer ME, Rae DS. et al. Comorbidity of mental dis-orders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511-2518 DOI: 10.1001/jama.1990.03450190043026.
    CrossrefPubMedGoogle Scholar
  • 2 Moggi F.. Doppeldiagnosen. Komorbidität psychischer Störungen und Sucht. Bern: Huber; 2007
    Google Scholar
  • 3 Gage SH, Hickman M, Zam mit S.. Association between cannabis and psychosis: Epidemiologic evidence. Biol Psychiatry 2016; 79: 549-556 DOI: 10.1016/j.biopsych.2015.08.001.
    CrossrefPubMedGoogle Scholar
  • 4 DGPPN e.V. für die Leitliniengruppe: S3-Leitlinie Schizophrenie. 2019: verfügbar unter (zuletzt geändert am 15.03.2019) https://www.awmf.org/leitlinien/detail/ll/038-009.html
    PubMed
  • 5 Gouzoulis-Mayfrank E.. Psychotische Störungen und komorbide Suchterkrankungen. Walter M, Gouzoulis-Mayfrank E. Psychische Störungen und Suchterkrankungen. Stuttgart: Kohlhammer; 2019: 103-117
    Google Scholar
  • 6 Beckmann D, Lowman KL, Nargiso J. et al. Substance-induced psychosis in youth. Child Adolesc Psychiatr Clin N Am 2020; 29: 131-143 DOI: 10.1016/j.chc.2019.08.006.
    CrossrefPubMedGoogle Scholar
  • 7 Weibell MA, Joa I, Bramness J. et al. Treated incidence and baseline characteristics of substance induced psychosis in a Norwegian catchment area. BMC Psychiatry 2013; 13: 319
    CrossrefPubMedGoogle Scholar
  • 8 Thompson A, Marwaha S, Winsper C. et al. Short-term outcome of substanceinduced psychotic disorder in a large UK first episode psychosis cohort. Acta Psychiatr Scand 2016; 134: 321-328
    CrossrefPubMedGoogle Scholar
  • 9 O’Connell J, Sunwoo M, McGorry P. et al. Characteristics and outcomes of young people with substance induced psychotic disorder. Schizophr Res 2019; 206: 257-262
    CrossrefPubMedGoogle Scholar
  • 10 Fraser S, Hides L, Philips L. et al. Differentiating first episode substance induced and primary psychotic disorders with concurrent substance use in young people. Schizophr Res 2012; 136: 110-115
    CrossrefPubMedGoogle Scholar
  • 11 Dawe S, Geppert L, Occhipinti S. et al. A comparison of the symptoms and shortterm clinical course in inpatients with substance-induced psychosis and primary psychosis. J Subst Abuse Treat 2011; 40: 95-101
    CrossrefPubMedGoogle Scholar
  • 12 Rugani F, Bacciardi S, Rovai L. et al. Symptomatological features of patients with and without Ecstasy use during their first psychotic episode. Int J Environ Res Public Health 2012; 9: 2283-2292
    CrossrefPubMedGoogle Scholar
  • 13 Hoch E, Friemel CM, Schneider M.. Cannabis: Potenzial und Risiko – Eine wissenschaftliche Bestandsaufnahme. Berlin, Heidelberg: Springe; 2019
    CrossrefGoogle Scholar
  • 14 Leweke FM, Piomelli D, Pahlisch F. et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012; 2: e94
    CrossrefPubMedGoogle Scholar
  • 15 Fiorentini A, Volonteri LS, Dragogna F. et al. Substance-induced psychoses: a critical review of the literature. Curr Drug Abuse Rev 2011; 4: 228-240
    CrossrefPubMedGoogle Scholar
  • 16 Atzendorf J, Rauschert C, Seitz NN. et al. The use of alcohol, tobacco, illegal drugs and medicines – an estimate of consumption and substance-related disorders in Germany. Dtsch Arztebl Int 2019; 116: 577-584 DOI: 10.3238/arztebl.2019.0577.
    CrossrefPubMedGoogle Scholar
  • 17 French ED.. delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci Lett 1997; 226: 159-162
    CrossrefPubMedGoogle Scholar
  • 18 Gessa GL, Melis M, Muntoni AL. et al. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 1998; 341: 39-44
    CrossrefPubMedGoogle Scholar
  • 19 Bossong MG, van Berckel BN, Boellaard R. et al. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacol 2009; 34: 759-766
    CrossrefPubMedGoogle Scholar
  • 20 Kuepper R, Ceccarini J, Lataster J. et al. Delta-9-tetrahydrocannabinol-induced dopamine release as a function of psycho-sis risk: 18F-fallypride positron emission tomography study. PLoS One 2013; 8: e70378
    CrossrefPubMedGoogle Scholar
  • 21 ElSohly MA, Mehmedic Z, Foster S. et al. Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biol Psychiatry 2016; 79: 613-619
    CrossrefPubMedGoogle Scholar
  • 22 Di Forti M, Quattrone D, Freeman TP. et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry 2019; 6: 427-436
    CrossrefPubMedGoogle Scholar
  • 23 Fattore L.. Synthetic cannabinoids-further evidence supporting the relationship between cannabinoids and psychosis. Biol Psychiatry 2016; 79: 539-548
    CrossrefPubMedGoogle Scholar
  • 24 Bramness JG, Rognli EB.. Psychosis induced by amphetamines. Curr Opin Psychiatry 2016; 29: 236-241
    CrossrefPubMedGoogle Scholar
  • 25 Drogenbeauftragte der Bundesregierung, Bundesministerium für Gesundheit (BMG), Bundesärztekammer (BÄK), Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN). S3-Leitlinie Methamphetamin-bezogene Störungen. 2016: Verfügbar unter https://www.aezq.de/mdb/edocs/pdf/literatur/s3-llmethamphetamin-bezogene-stoerungen-lang.pdf
    PubMed
  • 26 Orsolini L, Papanti GD, De Berardis D. et al. The “endless trip” among the NPS users: psychopathology and psychopharmacology in the hallucinogenpersisting perception disorder. A systematic review. Front Psychiatry 2017; 8: 240
    CrossrefPubMedGoogle Scholar
  • 27 DGPPN, Referat Notfallpsychiatrie. S2k-Leitlinie Notfallpsychiatrie (Stand: 13.04.2019) AWMF-Registernummer: 038-023. verfügbar unter https://www.awmf.org/uploads/tx_szleitlinien/038-023l_S2k_Notfallpsychiatrie_2019-05_1.pdf
    PubMed
  • 28 Adorjan K, Pogarell O.. Psychische Komorbiditäten. Falkai P, Hasan A. Praxishandbuch Schizophrenie – Diagnostik-Therapie-Versorgungsstrukturen. München: Elsevier; 2020: 50-69
    Google Scholar